Cardiometabolic Risk: Where GLP-1s Fit

GLP-1 receptor agonists entered public awareness as weight-loss drugs, but their most consequential evidence may be cardiometabolic. The question worth asking is not just “do they help people lose weight” but “where do they sit in the larger project of preventing heart attacks, strokes, and the slow metabolic decline that precedes them?” That requires zooming out from the scale.

Beyond weight, toward outcomes

What changed the conversation around this drug class was cardiovascular outcome data. The landmark example is SELECT, published in The New England Journal of Medicine in 2023. It randomized 17,604 adults who had established cardiovascular disease and overweight or obesity (BMI ≥27) but no diabetes to once-weekly semaglutide 2.4 mg or placebo, and followed them for a mean of about 40 months.

A cardiologist in a white coat discusses test results with a patient during a checkup, reflecting the kind of outcome data trials like SELECT are designed to produce

SELECT primary endpoint (CV death, nonfatal MI, or nonfatal stroke)	Result
Semaglutide 2.4 mg	6.5% of patients
Placebo	8.0% of patients
Hazard ratio	0.80 (95% CI 0.72–0.90, p<0.001)

That is a 20% relative reduction in major adverse cardiovascular events — a different and more meaningful endpoint than weight or blood sugar. It is the outcome those surrogate markers are only supposed to predict.

A drug that lowers a number on a lab report is interesting. A drug that lowers the rate of actual heart attacks and strokes is in a different category. SELECT — a 17,604-person trial showing a 20% cut in major cardiovascular events — is why this class is taken seriously beyond weight management.

The mechanisms are still being untangled. Some benefit likely flows from weight loss itself, some from improved glucose control, and some may be more direct — effects on inflammation, blood vessels, and blood pressure that aren’t fully explained by the pounds lost. Notably, in SELECT the cardiovascular benefit appeared early, before much weight had been lost, which argues for effects beyond weight alone. The relative contribution of each remains an area of active research.

An older adult practices yoga outdoors by a lake at dusk, representing the physical activity that remains a foundation of cardiometabolic risk reduction

Where they fit in the risk-reduction toolkit

GLP-1s do not replace the foundations of cardiometabolic prevention. They sit alongside them:

Established first-line measures — not smoking, blood pressure control, statins where indicated, and physical activity — remain the backbone, with decades of evidence.
GLP-1 agonists appear to add benefit, particularly for people with obesity, type 2 diabetes, or established cardiovascular disease.
They are tools, not substitutes. The evidence supports them as part of a strategy, not as a license to ignore everything else.

A blood pressure monitor displays a heart rate curve alongside a stethoscope, illustrating the cardiovascular measurements used to assess risk

Who the evidence speaks to

It is worth being precise about populations. SELECT enrolled only people who already had established cardiovascular disease plus overweight or obesity — a high baseline-risk group. Extending its findings to lower-risk individuals — say, a metabolically healthy person taking the drug purely cosmetically — is an extrapolation the trial does not directly support. Benefit demonstrated in high-risk groups does not automatically transfer to low-risk ones, and because absolute event rates are lower in healthier people, the risk-benefit math shifts accordingly.

The takeaway

GLP-1 agonists have earned a legitimate place in cardiometabolic medicine, with hard outcome data — not just surrogate markers — behind them for higher-risk populations. They complement rather than replace the well-established basics of prevention. The honest boundary is around who benefits most: the evidence is strongest where baseline risk is highest, as in SELECT, and thinner the further you move from those populations.